gmp-verlag.de
 
 
Shopping cart
Your shopping cart is empty

Show shopping cart...
 
 
PDA Parenterals Conference

From 26-28 October, 2010 the PDA Parenterals Conference will be held in Berlin.

This outstanding event will cover the very important topics:

  • Future of Parenterals
  • Packaging and Impact on Quality
  • Manufacturing Flexibility and Control
  • Innovative Plants
  • Monitoring Technologies
  • Medical and Application Devices
  • Regulatory Trends

Don´t miss this interesting conference in Berlin, Germany.

Brochure of PDA Parenterals Conference 2010, October 26-28

 
 
KNOWLEDGE IS POWER!

The GMP MANUAL is the most powerful and dependable reference tool in the world.

 

Indispensable for pharmaceutical manufacturers, suppliers, consultants and engineering companies that need the most updated information available. Start right away with GMP MANUAL – for only 695 Euro. Order now your personal copy.

 

Read more...

 

Updates Forecast & History

GMP MANUAL Update No. 08

What is new?

The eighth update of the GMP MANUAL encompasses approx. 650 pages for the
printed version. We have outlined the contents of Update 08 below:

“GMP in Practice”

Updated Chapters:

  • Chapter 3 Premises:
    3.A: Official Requirements
    3.C: Room Classes
    3.F: Building Services
  • Chapter 8: Cleaning Validation (entire chapter)
  • Chapter 9: Computer Validation:
    9.B Regulatory Aspects
    9.D Risk Analysis and System Classification
  • Chapter 11: Production
    11.E.3.2 US Requirements

New Chapters:

  • Chapter 3 Premises:
    3.E: Barrier Systems and Isolators
    3.H: Process Gases
    3.I: Qualification of Premises and Air-Conditioning Systems
    3.J: Monitoring of HVAC Systems
    3.K: References
  • Chapter 8: Cleaning Validation:
    8.K References
  • Chapter 9: Computer Validation:
    9.H References
  • Chapter 14: Laboratory and analytical controls:
    14.L Pharmacopoeias
    14.M References

“GMP Regulations”

Updated Chapters:

  • Chapter A: Information
    A.3: Abbreviations
  • Chapter D: USA: CFR and FDA Guidelines
    D.13: 21 CFR Part 820
    D.16: Federal Food, Drug, and Cosmetic Act (link to revised version)
  • Chapter E: ICH-Guidelines
    E.4.B: ICH Q4B Annex 2 and Annex 3 (now Step 4)

New Chapters:

  • Chapter D: USA: CFR and FDA Guidelines
    D.15: Guidance for Industry: CGMP for Phase 1 Investigational Drugs
  • Chapter E: ICH-Guidelines
    E.4.B: ICH Q4B: Annex 4–10

 

GMP in Practice (File 1–3)

File 1

  • Chapter 3 Premises The entire chapter “Premises” has been subject to a comprehensive revision. Official and general requirements – the former chapters 3.A and 3.B – were updated and combined in a new chapter 3.A Official Requirements (Dr. M. Hiob / R. Gomez). Chapter 3.C Room classes (formerly 3.D) was updated in order to reflect the requirements of the revised Annex 1 to the EU GMP Guide (Dr. H. Schicht). Chapter 3.F Building Services was elaborated and restructured (Dr. Th. Schreiner). As part of the revision of the chapter, several new topics were introduced as well:
  • Barrier Systems and Isolators (chapter 3.E) are techniques of incremental importance with view to the increasing requirements regarding aseptic processing. Dr. Hans Schicht describes technical aspects and construction principles, discusses implementation options and decontamination techniques and defines regulatory and normative requirements.
  • Chapter 3.H Process Gases (Dr. Thomas Schreiner) describes quality requirements for compressed air and other pharmaceutical gases and outlines GMP-aspects related to the generation, storage, transport and distribution systems for process gases. The chapter includes information on qualification, maintenance and monitoring of the respective systems.
  • The Qualification of premises and air-conditioning systems is subject of chapter 3.I (Dr. Hans Schicht). Regulatory and normative requirements are described and their implementation in qualification plans and reports is shown by means of illustrative checklists. Beyond this, the author explains the requirements for periodical and extraordinary requalification.
  • Chapter 3.J Monitoring of HVAC Systems (Dr. Hans Schicht) gives a comprehensive overview on measurement, registration and storage of data impacting safety and quality of drug products. A distinction has to be made between physical and microbiological data. Alarm- and action limits have to be defined, and data should be subject to regular trend analyses.

File 2

  • Chapter 8 Cleaning Validation This chapter, which mainly focused on European and PIC/S requirements, was completely reviewed by Ralph Gomez and amended by US requirements regarding cleaning validation. The overall information was checked for up-to-dateness and amended as necessary.
  • Chapter 9 Computer Validation Chapter 9.B was updated to reflect the current state of Regulatory Requirements. Provisions of the recent revision of 21CFR 211 in the context of computerized systems and the need for doublechecks by a second person are mentioned, and reference is made to the new GAMP® 5 (Dr. Peter Bosshard).
  • Chapter 9.D Risk Analysis and System Classification was updated in order to reflect changes in system classification from GAMP® 4 to 5 (Dr. Peter Bosshard).
  • Chapter 11 Production Within chapter 11.E Environmental monitoring, section 11.E.3.2 US requirements has to be replaced due to an editorial mistake.
  • References (3.K, 8.K, 9.H. 14.M) Starting with the actual update, we will provide subchapters with compilations of topic-specific references to each of the chapters in the “GMP in Practice” part. Regulatory requirements of different regions, international guidelines and standards as well as scientific publications are clearly represented in the respective subchapters.

GMP Regulations (File 4–5)

File 4

  • Chapter A Information
    Chapter A.3 Abbreviations has been reviewed and updated.
  • Chapter D USA: CFR and FDA Guidelines
    Chapter D.13 was updated and provides now the recent version of 21 CFR Part 820.
    Chapter D.16 shows the table of contents of the Federal Food, Drugs, and Cosmetics Act and includes the actual web-link to this huge document.
    Chapter D.15 introduces one more FDA Guidance into the GMP MANUAL, the Guidance for Industry: CGMP for Phase 1 Investigational Drugs. This document describes the FDA’s expectations and recommendations for applying CGMP practices to the manufacture and control of investigational drugs for phase 1 clinical trials.

File 5

  • Chapter E ICH Guidelines
    With the current update, chapter E.4.B ICH Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions is updated (Annex 2 and 3) and extended (Annexes 4 – 10). This chapter gives an overview on harmonized pharmacopoeial texts for use in USA, Europe and Japan.

With this update 08 we deliver to you a lot of new and revised documents which will keep the GMP MANUAL up-to-date. Take the time (approx. 20 min.) to file the pages into your GMP MANUAL.

If you have any comments, questions, references or suggestions for improvement, please do not hesitate to contact us. We will check every request in order to improve the GMP MANUAL. So that the GMP MANUAL continues to be: The most powerful GMP reference tool in the world.

Please contact: service@gmp-publishing.com

Comments
No comment have jet been written about this news